Protocol design and development
Data-Driven Strategies for Neurodegenerative and Neurodevelopmental Disorders.

Redenlab’s clinical trial services are grounded in clinical need. We bring trial expertise, clinical experience and an understanding of the need for meaningful outcome measures to enhance any clinical trial. Redenlab employ key opinion leaders across multiple domains to ensure your endpoints are best in class. Our technology offerings are tailored to traditional in-clinic testing, at home protocols and virtual trials.
Data-Driven Strategies for Neurodegenerative and Neurodevelopmental Disorders.
Flexible hardware and software options tailored to trial requirements. Our mobile applications and in-browser tools enable scalable, low-burden, and frequent self-monitoring and data capture in the patient's home environment using off-the-shelf devices
Sophisticated data analysis pipelines focused on providing evidence informed outcomes. We leverage machine learning for data cleaning and quality assurance, which transforms complex, noisy audio (e.g., in-home recordings) into usable, high-fidelity data, a process that is critical for reproducibility and scalability
Validated and audited Quality Management System supporting company-wide activities.
Comprehensive management of trial aspects, from site training, hardware leasing, and in-trial compliance to study close.
Designing, building, and running virtual trials with protocols suitable for at home patient participation, servicing Phase 0-IV studies. This remote capability is especially important for neurological disorders, where decline can be individualized and rapid, requiring frequent monitoring and quick detection of change for drug adjustment.
Robust, insightful, and fit-for-purpose statistical support for clinical research
Redenlab’s guidance on minimizing risk to patients and staff during speech recordings
For more information
If you are interested in seeing how Redenlab can help your organisation, please fill in the form and we’ll get in contact with you.
